Bio-Techne Corporation (NASDAQ: TECH) is a Healthcare company (Biotechnology) with a market capitalization of $11.4B. The Maz Rating grades it against the other companies in its sector.
Bio-Techne Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $72.63, Bio-Techne Corporation trades at 66.1x trailing earnings, 9.3x sales and 5.3x book value, with an EV/EBITDA of 34.5. Over the last twelve months it generated about $1.2B of revenue and $173M of net income. It runs a gross margin of 65.8%, an operating margin of 19.6% and a net margin of 14.0%. It shows return on equity of 8.2%, return on invested capital of 7.3% and a free cash flow yield of 2.7%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 2.28. Over the past 52 weeks the share price ranged from $43.20 to $72.88, with a beta of 1.27.
Bio-Techne Corporation pays a dividend yielding 0.55%, with 29% of earnings paid out. Its Maz Dividend Score is 2.17 out of 5, ranked against the other dividend payers in its sector (Safety 3.57, Growth 2.50, Yield 1.37, Consistency 2.66).
26 Wall Street analyst ratings cover the stock: 12 Buy and 14 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Bio-Techne Corporation (TECH) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.77% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.27% / 30% · Interest income / Revenue 0.65% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.77% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.10% / 33% · Receivables / Mkt Cap (36m) 1.85% / 49% · Interest income / Revenue 0.65% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.77% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.10% / 33.33% · Receivables / Mkt Cap (24m) 1.85% / 33.33% · Interest income / Revenue 0.65% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 8.49% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 9.70% / 33.33% · Receivables / Avg Assets (4Q) 8.05% / 33.33% · Interest income / Revenue 0.65% / 5% | Pass |
| FTSE | Debt / Total Assets 7.58% / 33.33% · (Cash+ST Inv) / Total Assets 13.3% / 33.33% · (Cash+Recv) / Total Assets 21.3% / 33.33% · Interest income / Revenue 0.65% / 5% | Pass |
Yes. As of September 2026, Bio-Techne Corporation (TECH) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Bio-Techne Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.65% of each dividend: Bio-Techne Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.